OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Q4 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the RMR Group Fiscal Fourth Quarter ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Good morning, and welcome to the RMR Group fiscal fourth quarter 2024 earnings conference call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the ...

Under Strategic Platform License (SPL) agreements, the company worked with Vertex Pharmaceuticals and CRISPR Therapeutics ... future results of operations or financial condition, business strategy and ...

Which is why EU users have an opt-in option instead, with the General Data Protection Regulation protecting its digital users ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

“Building a strong personal brand can open new opportunities for growth—whether that be for your own status in the industry ...